With no effective COVID-19 vaccine yet developed, UK has now secured the orders of three different vaccine types in the quantity of potentially 230 million doses.
The latest deals signed by the UK saw it secured 90 million more doses of potential COVID-19 vaccine. The UK government signed these deals with renowned firms like Pfizer Inc (PFE.N), BioNTech (22UAy.F), and Valneva (VLS.PA), announced by the UK business ministry on Monday, without disclosing any financial terms.
According to the business ministry, the deals with Pfizer/BioNTech is for 30 million doses of their experimental vaccine, while the initial deal with the French group Valneva is for 60 million doses, with an option to procure 40 million more only on the condition that it proves to be effective, safe, and suitable.
"UK's Oxford University COVID-19 vaccine shows positive results in first phase of human trials" https://t.co/GXHPULKb40
— Rabi Sankar Mishra (@RabiRSM) July 21, 2020
These deals saw the UK secure a total of 230 million doses of three different types of vaccines, as the govt. previously announced a deal of 100 million doses with the firm AstraZeneca (AZN.L), which is developing a potential COVID-19 vaccine in partnership with the University of Oxford.
“This new partnership with some of the world’s foremost pharmaceutical and vaccine companies will ensure the UK has the best chance possible of securing a vaccine that protects those most at risk,” said the business minister Alok Sharma.
The minister added that the UK has also launched a website that invites volunteers to sign up for vaccine studies. He said it is truly a global endeavor to find a working vaccine for COVID-19, and that the govt. is taking all the measures to ensure their citizens get access to an effective as well as safe COVID-19 vaccine as soon as possible.
Pfizer and Biotech are developing an mRNA-based vaccine, BNT162, for COVID-19. According to Pfizer, It is expected that the vaccine will get regulatory approval by October, as it is already set to enter Phase 2/3 of the clinical trials.
The firms have an aim to produce around 100 million dozes of their BNT162 vaccine, and potentially produce more than 1.2 billion doses of the vaccine by the end of 2021, based upon the success of their vaccine.
While the Valneva vaccine VLA2001 is still in its pre-clinical trial stages, and the firm is aiming to move into the clinical trials phase by the end of this year.
The UK has been one of the worst COVID-19 affected countries in the world and has suffered more than 45,000 deaths from the deadly virus.